Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05456685 · ClinicalTrials.gov registry record · Phase 2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
A Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT05456685 is a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 125 participants, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05456685, a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Mirvetuximab soravtansine
Study Locations (20)
California
- Women'S Cancer Research Network - Cogi /ID# 268912 - Fresno
- Providence - St. Jude Medical /ID# 268911 - Fullerton
- Moores Cancer Center /ID# 268888 - La Jolla
- USC Norris Comprehensive Cancer Center /ID# 268964 - Los Angeles
- University of California Los Angeles Medical Center /ID# 268883 - Los Angeles
- Hoag Memorial Hospital Presbyterian /ID# 268907 - Newport Beach
- UC Davis Comprehensive Cancer Center /ID# 269085 - Sacramento
- Scripps Md Anderson - Prebys Cancer Center /ID# 268966 - San Diego
- California Pacific Medical Center - Van Ness Campus /ID# 268886 - San Francisco
Florida
- AdventHealth Orlando /ID# 268920 - Orlando
- Sarasota Memorial Hospital /ID# 268882 - Sarasota
- Moffitt Cancer Center /ID# 269089 - Tampa
Massachusetts
- Massachusetts General Hospital /ID# 268879 - Boston
- Dana-Farber Cancer Institute /ID# 268881 - Boston
Arizona
- University of Arizona Cancer Center /ID# 268906 - Tucson
Connecticut
- Smilow Cancer Hospital at Yale New Haven /ID# 268889 - New Haven
Georgia
- Winship Cancer Institute of Emory University /ID# 268913 - Atlanta
Illinois
- Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 268957 - Chicago
Louisiana
- Women'S Cancer Care /ID# 268898 - Covington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05456685
The ClinicalTrials.gov registry entry for NCT05456685 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (51% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT05456685 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05456685 about?
NCT05456685 is a clinical study titled "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer". IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer follo...
What is the current status of trial NCT05456685?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2022-09-28. Estimated completion is 2026-11.
What conditions does trial NCT05456685 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Ovarian Cancer.
What interventions are being tested in trial NCT05456685?
The interventions under investigation include: Carboplatin (DRUG), Mirvetuximab soravtansine (DRUG).
Who is sponsoring clinical trial NCT05456685?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05456685 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.